Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro

World Journal of Gastroenterology

Volumn 10, Issue 3, 2004, Pages 393-399

  Kumar, Manoj ^a   Liu, Zheng Ren ^a   Thapa, Laxmi ^a   Chang, Qing ^a   Wang, Da Yu ^a   Qin, Ren Yi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; COMPLEMENTARY DNA; GELATINASE A; MESSENGER RNA; PEROXIDASE; SOMATOSTATIN RECEPTOR 2; STREPTAVIDIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLONE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; OPTICAL DENSITY; PANCREAS CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TUMOR VASCULARIZATION; VECTOR CONTROL;

EID: 1142275460     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i3.393     Document Type: Article

References (39)

1. Reisine T. Somatostatin receptors. Am J Physiol 1995; 269(6 Pt 1):G813-G820
2. Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C. Regulation of cell proliferation by somatostatin. Ann Endocrinol 2002; 63(2 Pt 3): 2S13-2S18
3. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalhoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56: 1823-1827
4. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997; 57: 956-962
5. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988; 95: 760-763
6. Sulkowski U, Buchler M, Pederzoli P, Arnold R, Dinse P, Kay A, Haus U, Beger HG. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur J Cancer 1999; 35: 1805-1808
7. Burch PA, Block M, Schroeder G, Kugler JW, Sargent DJ, Braich TA, Mailliard JA, Michalak JC, Hatfield AK, Wright K, Kuross SA. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group study. Clin Cancer Res 2000; 6: 3486-3492
8. Fisher WE, Doran TA, Muscarella P 2nd, Boros LG, Ellison EC, Schirmer WJ. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 1998; 90: 322-324
9. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-1155
10. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003; 2: 8
11. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, Calvin DA, Nodzenski E, Pejovic M, Kufe DW, Posner MC, Weichselbaum RR. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002; 8: 47-54
12. Itakura J, Ishiwata T, Fries H, Fujii H, Matsumoto Y, Buchler MW, Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3: 1309-1316
13. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-2245
14. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79: 1553-1563
15. Stock UA, Wiederschain D, Kilroy SM, Shum-Tim D, Khalil PN, Vacanti JP, Mayer JE Jr., Moses MA. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem 2001; 81: 220-228
16. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimaldomain organization required for secretion, latency, and activity. Cancer Res 2000; 60: 4745-4751
17. Deng SJ, Bickett DM, Mitchell JL, Lambert MH, Blackburn RK, Carter HL 3rd, Neugebauer J, Pahel G, Weiner MP, Loss ML. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 2000; 275: 31422-31427
18. Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez-Otin C, Murphy G, Knauper V. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000; 275: 14809-14816
19. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix-metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2000; 356(Pt 3): 705-718
20. Nar H, Werle K, Bauer MM, Dollinger H, Jung B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol 2001; 312: 743-751
21. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-355
22. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998; 82: 642-650
23. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002; 80: 105-110
24. Koshiba T, Hosotani R, Wada M, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M. Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today 1997; 27: 302-304
25. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Buchler M, Adler G, Gress TM. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20
26. Matsushita A, Onda M, Uchida E, Maekawa R, Yoshioka T. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int J Cancer 2001; 92: 434-440
27. Rauly I, Saint-Laurent N, Delesque N, Buscail L, Esteve JP, Vaysse N, Susini C. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH3T3 cells. J Clin Invest 1996; 97: 1874-1883
28. Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002; 65: 200-206
29. Wang C, Tang C. Inhibition of human gastric cancer metastasis by ocreotide in vitro and in vivo. Zhonghua Yixue Zazhi 2002; 82: 19-22
30. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001; 92: 545-550
31. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364
32. Stipa F, Lucandri G, Limiti MR, Bartolucci P, Cavallini M, Di Carlo V, D'Amato A, Ribotta G, Stipa S. Angiogenesis as a prognostic indicator in pancreatic ductal adenocarcinoma. Anticancer Res 2002; 22: 445-449
33. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 794-814
34. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364
35. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-844
36. Millauer B, Shawver LK, Platet KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-579
37. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. Monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002; 5: 35-44
38. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 1997; 272: 13869-13876
39. Bloomston M, Zervos EE, Rosemurgy AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials. Ann Surg Oncol 2002; 9: 668-674